STAAR Surgical Company (STAA) - Stock Analysis
Last updated: Apr 12, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
STAAR Surgical has a fresh revenue surprise and momentum: pre‑announced Q1 net sales above ~$90M drove a ~25% two‑day spike, and FDA expansion of EVO/EVO+ ICL indication (21–60 years) broadens its market. Shares are ~42% above their 21‑day mean, with strong volume and activist/institutional buying, making STAA a high‑velocity near‑term trade around the formal earnings release.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • High gross margin • Large operating losses • Strong liquidity STAA pairs very high gross margins and strong liquidity with low leverage, but heavy SG&A/R&D drive large operating losses and negative cash flow that threaten the investment case.
Price Behavior
Key Price Behavior Insights: • Momentum breakout • Elevated volatility • Pullback risk Support Level: $20; $17–$19 Resistance Level: $26.40 STAA surged above its last month SMA (~$19.6) to a new high near $26.4, signaling a momentum breakout but increasing mean‑reversion risk with key support around $20 and the $17–$19 consolidation band.
Sentiment & News
Key News Insights: • Insider buying • Strong preliminary sales • Valuation reset STAAR shows renewed investor confidence after heavy insider/institutional buying and preliminary Q1 sales well above expectations, driving a >25% intraday rally and analyst revisions.
AI Summary
STAAR's narrative has shifted from a distressed device maker to an early-stage growth re-rating driven by China destocking resolution, EVO+ ICL launch and FDA age-expansion, but this premium is only justified if the company converts those one-off/regulatory uplifts into consecutive quarters of organic revenue growth, margin stability, and visible operating cash‑flow improvement. Watch quarterly organic sales (ex‑channel restock), SG&A cadence versus revenue, and China adoption—failure to show sustainable pickup or a return to aggressive spend would quickly reverse the re‑rating and risk mean reversion toward the $17–$20 band.
Description
STAAR Surgical Company designs, manufactures and sells implantable intraocular lenses and the delivery systems used to place them, along with preloaded cataract lenses, injector components and related surgical instruments. Its products, which address refractive errors and cataract treatment, are marketed primarily to ophthalmologists and surgical centers through a mix of direct sales forces and distributor networks across North America, Europe and Asia. The company was founded in 1982 and is headquartered in Lake Forest, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 10 | Apr 17 | STAA | STAAR Surgical Company | STAAR Surgical has a fresh revenue surprise and momentum: pre‑announced Q1 net sales above ~$90M drove a ~25% two‑day spike, and FDA expansion of EVO/EVO+ ICL indication (21–60 years) broadens its market. Shares are ~42% above their 21‑day mean, with strong volume and activist/institutional buying, making STAA a high‑velocity near‑term trade around the formal earnings release. | Active | +1.1% |